News Headlines
-
Lonza And CMS Sign License Agreement For NeuroPortal TfR1 Blood-Brain Barrier Technology
11/16/2026
Lonza and China Medical System Holdings Limited (CMS) announced today a global exclusive license agreement for the use of Lonza’s NeuroPortal transferrin receptor 1 (TfR1) blood-brain barrier (BBB) technology in up to two products targeting neurodegenerative diseases.
- Simtra Biopharma Solutions Celebrates Opening Of $250+ Million Bloomington Manufacturing Expansion 11/13/2026
-
License Agreement With Link For Cefiderocol, A Treatment For Gram-Negative Bacterial Infections, In Singapore And Malaysia
11/13/2026
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced today that it has entered into a license agreement (the “Agreement”) with Link Healthcare Singapore Pte Ltd (“Link”), headquartered in Singapore, for the development and market development of cefiderocol, a treatment for Gram-negative bacterial infections discovered by Shionogi, in Singapore and Malaysia.
-
Andelyn Biosciences To Develop And Manufacture AAV Gene Therapy For Celliaz To Treat Retinitis Pigmentosa
11/12/2026
Andelyn Biosciences (Andelyn), a leading US-based patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), and Celliaz Co., Ltd., a South Korean biotechnology company developing next-generation regenerative therapeutics for retinal degenerative diseases, today announced a strategic partnership to advance CLZ002, an investigational adeno-associated virus (AAV)-based gene therapy for retinitis pigmentosa (RP).
-
Ori Biotech Strengthens Supply Chain Resilience, Business Continuity And GMP Readiness With Europlaz Partnership
11/11/2026
Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, and Europlaz (EPZ), a leading UK contract manufacturer in GMP grade bioprocessing tools and equipment, today announced a strategic partnership to support Ori delivering its GMP-ready IRO consumable family to cell and gene therapy developers worldwide.
-
ProBio Enters Exclusive Global Licensing Agreement with AbTis To Develop Next-Generation ADC Asset
11/10/2026
ProBio, a global contract research, development, and manufacturing organization (CRDMO), today announced that it has entered into an exclusive global licensing agreement with AbTis Co., Ltd., a South Korean biotechnology company and subsidiary of Dong-A ST, specializing in site-specific conjugation technologies for antibody-drug conjugates (ADCs).
-
Omniose Announces Its Acquisition By AstraZeneca
11/10/2026
Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.
-
AGC Biologics Partners With Child's Cure Genetic Research To Pursue mRNA-Based Therapeutic For Severe Epileptic Disorder
11/10/2026
In a world where patients with CDKL5 deficiencies can suffer 40 to 60 epileptic seizures a day, a contract biopharmaceutical manufacturer and a parent-founded foundation will partner on early-stage messenger RNA development to find a long-term treatment for the rare neurodevelopmental disease.
-
Mendus And NorthX Biologics Expand Collaboration To Include Production Of Memory NK Cell Therapies
11/10/2026
Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on transforming immunotherapies targeting myeloid blood cancers, today announced that it has been awarded a SEK 977,300 grant by Vinnova, Sweden's innovation agency, to establish production of memory NK cell-based therapies, together with its manufacturing partner NorthX Biologics.
-
Ocugen And Celairis Therapeutics Enter Into Exclusive License Agreement For OCU400 In Australia, New Zealand, And ASEAN
11/10/2026
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and Celairis Therapeutics Holdings Pty Ltd. ("Celairis"), a Sydney-based in-licensing, development, and commercialization biopharmaceutical company focused on Australia, New Zealand, Taiwan, and ASEAN, today announced the execution of an exclusive license agreement (the "License Agreement") granting Celairis an exclusive license to commercialize OCU400, Ocugen's investigational modifier gene therapy for the treatment of RP, in Australia, New Zealand, and ASEAN markets (the "Territory").